Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): a post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN (AFT-29)
- Citation:
- J Clin Oncol vol 40 (16_suppl) 8011
- Meeting Instance:
- ASCO 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- AFT
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3854
- Pharmas:
- JNJ
- Grants:
- Corr. Author:
- Authors:
- Cesar Rodriguez Jonathan L. Kaufman Jacob Laubach Douglas W. Sborov Brandi Reeves Ajai Chari Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr Nitya Nathwani Nina Shah Naresh Bumma Andrzej Jakubowiak Robert Z. Orlowski Huiling Pei Annelore Cortoos Sharmila Patel Thomas S. Lin Paul G. Richardson Peter M. Voorhees
- Networks:
- CA043, CA824, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, OR013
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: